Prelude Capital Management, LLC Summit Therapeutics Inc. Transaction History
Prelude Capital Management, LLC
- $934 Million
- Q2 2025
Shares
1 transactions
Others Institutions Holding SMMT
# of Institutions
261Shares Held
90.7MCall Options Held
4.55MPut Options Held
3.34M-
Baker Bros. Advisors LP New York, NY33.7MShares$866 Million7.27% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.67MShares$223 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$203 Million0.0% of portfolio
-
State Street Corp Boston, MA4.02MShares$103 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.91MShares$100 Million0.01% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $5.17B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...